RT @CharuAggarwalMD
@DrSteveMartin @TumorBoardTues @MPishvaian @DAielloMD @JohnEbbenMDPhD @ChristianRolfo Given that oncogenic drivers are mutually exclusive (majority of the time), finding of a non-actionable mutation such as KRAS G12D can be immensely meaningful, to begin therapy which is #MolecularlyInformed #ctDNA

RT @CharuAggarwalMD
@DrSteveMartin @TumorBoardTues @MPishvaian @DAielloMD @JohnEbbenMDPhD @ChristianRolfo Given that oncogenic drivers are mutually exclusive (majority of the time), finding of a non-actionable mutation such as KRAS G12D can be immensely meaningful, to begin therapy which is #MolecularlyInformed #ctDNA